Astra, Sanofi Rise on Optimism Over Pfizer’s US Price Deal (2)

Oct. 1, 2025, 11:20 AM UTC

AstraZeneca Plc, Roche Holding AG and Sanofi led gains among European drugmakers on optimism that rival Pfizer Inc.’s pricing agreement with the US paves the way for others to strike similar deals.

Astra shares surged as much as 7% in London trading, the biggest gain in almost six months. The UK drugmaker gets almost half of its revenue in the US. Roche rose as much as 6.2%, also close to a half-year record, and Sanofi 4.6%.

Pfizer secured a three-year grace period from President Donald Trump’s promised tariffs on drugs in a deal announced Tuesday, providing a blueprint ...

Learn more about Bloomberg Law or Log In to keep reading:

See Breaking News in Context

Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.

Already a subscriber?

Log in to keep reading or access research tools and resources.